Ataraxis AI, a developer of AI-powered prognostic tools for oncology, has announced a strategic collaboration with MEDSIR, a global leader in oncology research, to integrate artificial intelligence into multiple major international clinical trials. The studies will analyze data from over 1,000 patients, aiming to identify biomarkers that optimize treatment strategies for breast cancer, including CDK4/6 inhibitors and antibody-drug conjugates (ADCs). Read More